175 related articles for article (PubMed ID: 32064174)
21. Assessing Functional Roles of the Senescence-Associated Secretory Phenotype (SASP).
Malaquin N; Tu V; Rodier F
Methods Mol Biol; 2019; 1896():45-55. PubMed ID: 30474839
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.
Kitamura H; Ohno Y; Toyoshima Y; Ohtake J; Homma S; Kawamura H; Takahashi N; Taketomi A
Cancer Sci; 2017 Oct; 108(10):1947-1952. PubMed ID: 28749573
[TBL] [Abstract][Full Text] [Related]
23. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.
Molavi O; Ma Z; Hamdy S; Lai R; Lavasanifar A; Samuel J
Immunol Cell Biol; 2008; 86(6):506-14. PubMed ID: 18392040
[TBL] [Abstract][Full Text] [Related]
24. SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells.
Canino C; Mori F; Cambria A; Diamantini A; Germoni S; Alessandrini G; Borsellino G; Galati R; Battistini L; Blandino R; Facciolo F; Citro G; Strano S; Muti P; Blandino G; Cioce M
Oncogene; 2012 Jun; 31(26):3148-63. PubMed ID: 22020330
[TBL] [Abstract][Full Text] [Related]
25. B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.
Zhao X; Zhang Z; Moreira D; Su YL; Won H; Adamus T; Dong Z; Liang Y; Yin HH; Swiderski P; Pillai RK; Kwak L; Forman S; Kortylewski M
Mol Ther; 2018 Mar; 26(3):695-707. PubMed ID: 29433938
[TBL] [Abstract][Full Text] [Related]
26. Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.
Kortylewski M; Moreira D
Cancer Immunol Immunother; 2017 Aug; 66(8):979-988. PubMed ID: 28214929
[TBL] [Abstract][Full Text] [Related]
27. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
28. STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.
Bryson BL; Junk DJ; Cipriano R; Jackson MW
Cell Cycle; 2017 Feb; 16(4):319-334. PubMed ID: 27892764
[TBL] [Abstract][Full Text] [Related]
29. The protein kinase D1-mediated classical protein secretory pathway regulates the Ras oncogene-induced senescence response.
Su Y; Wang P; Shen H; Sun Z; Xu C; Li G; Tong T; Chen J
J Cell Sci; 2018 Mar; 131(6):. PubMed ID: 29420297
[TBL] [Abstract][Full Text] [Related]
30. Anti-cancer effect of marchantin C via inducing lung cancer cellular senescence associated with less secretory phenotype.
Zhang XL; Ji XT; Sun B; Qian LL; Hu XL; Lou HX; Yuan HQ
Biochim Biophys Acta Gen Subj; 2019 Oct; 1863(10):1443-1457. PubMed ID: 31103748
[TBL] [Abstract][Full Text] [Related]
31. STAT3/NF-κB-Regulated Lentiviral TK/GCV Suicide Gene Therapy for Cisplatin-Resistant Triple-Negative Breast Cancer.
Kuo WY; Hwu L; Wu CY; Lee JS; Chang CW; Liu RS
Theranostics; 2017; 7(3):647-663. PubMed ID: 28255357
[TBL] [Abstract][Full Text] [Related]
32. Senescence in the Development and Response to Cancer with Immunotherapy: A Double-Edged Sword.
Battram AM; Bachiller M; Martín-Antonio B
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32570952
[TBL] [Abstract][Full Text] [Related]
33. Cellular senescence and senescence-associated secretory phenotype via the cGAS-STING signaling pathway in cancer.
Loo TM; Miyata K; Tanaka Y; Takahashi A
Cancer Sci; 2020 Feb; 111(2):304-311. PubMed ID: 31799772
[TBL] [Abstract][Full Text] [Related]
34. Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer.
He Q; Xue S; Tan Y; Zhang L; Shao Q; Xing L; Li Y; Xiang T; Luo X; Ren G
Cancer Lett; 2019 Apr; 448():94-104. PubMed ID: 30742942
[TBL] [Abstract][Full Text] [Related]
35. CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3.
Tang Q; Jiang J; Liu J
Inflammation; 2015 Dec; 38(6):2049-56. PubMed ID: 26047948
[TBL] [Abstract][Full Text] [Related]
36. Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.
Katlinskaya YV; Katlinski KV; Yu Q; Ortiz A; Beiting DP; Brice A; Davar D; Sanders C; Kirkwood JM; Rui H; Xu X; Koumenis C; Diehl JA; Fuchs SY
Cell Rep; 2016 Apr; 15(1):171-180. PubMed ID: 27052162
[TBL] [Abstract][Full Text] [Related]
37. Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.
Vilgelm AE; Johnson CA; Prasad N; Yang J; Chen SC; Ayers GD; Pawlikowski JS; Raman D; Sosman JA; Kelley M; Ecsedy JA; Shyr Y; Levy SE; Richmond A
J Natl Cancer Inst; 2016 Jun; 108(6):djv406. PubMed ID: 26719346
[TBL] [Abstract][Full Text] [Related]
38. MLL1 is essential for the senescence-associated secretory phenotype.
Capell BC; Drake AM; Zhu J; Shah PP; Dou Z; Dorsey J; Simola DF; Donahue G; Sammons M; Rai TS; Natale C; Ridky TW; Adams PD; Berger SL
Genes Dev; 2016 Feb; 30(3):321-36. PubMed ID: 26833731
[TBL] [Abstract][Full Text] [Related]
39. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
[TBL] [Abstract][Full Text] [Related]
40. A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy.
Zhang W; Yu W; Cai G; Zhu J; Zhang C; Li S; Guo J; Yin G; Chen C; Kong L
Cell Death Dis; 2018 Oct; 9(11):1098. PubMed ID: 30368518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
